Bekform 400 : Beclomethasone & Formoterol Rotacaps

Bekform is the rationale, guideline recommended, cost-effective combination of Inhaled corticosteroid + Long acting beta 2 agonist (ICS+LABA), preferably catering to the need of primary care practitioner.

Bekform combines the time tested ICS Beclomethasone (BDP) and rapid acting bronchodilator formoterol fumarate.

The major concern of primary care is about the high cost of asthma medication which may act as a barrier for initiating and adhering with asthma therapy leading to uncontrolled asthma, disability and absenteeism.

Bekform is the first brand in respiratory market, available in pack of ten Rotacaps, making asthma treatment accessible to all asthmatic patients. Bekform provides a cost effective therapy, which reduces the initial outlay for the patient & thus prevents the patient from discontinuing the medication due to high cost.

BDP the first inhaled corticosteroid introduced in 1972, represented a significant therapeutic advance as its low oral bioavailability, high systemic clearance and inhalation formulation imparted a much wider therapeutic ratio than any oral corticosteroid. Over the past 30-35 years a number of clinical trials published on beclomethasone have well established this molecule. BDP gets metabolised by esterase enzymes to beclomethasone-17-monopropionate, which is the active metabolite and has potent anti inflammatory activity. BDP administered by inhaled route acts exclusively in the airways and at usual doses, has no systemic effects and does not suppress the hypothalamic-pituitary-adrenal axis (HPA). One of the characteristics of beclomethasone, is its hepatic metabolization into inactive metabolite; thus reducing the systemic availability of the drug.

Formoterol, a selective beta2- agonist, produces effective dose proportional bronchodilation in patients with reversible obstructive airway disease. Formoterol is a highly potent, long-acting beta2- agonist, combining the clinical advantages of rapid onset of action which is similar to salbutamol with the advantage of longer duration of action around 12 hr. Formoterol is approximately 107 times more potent than salmeterol and 323 times more potent than salbutamol in relaxing isolated human bronchi.

INDICATIONS
Bekform is indicated in the regular treatment of asthma, where use of a combination (long-acting beta2-agonist and inhaled corticosteroid) has been found to be appropriate.

DOSAGE AND ADMINISTRATION
Asthma
Adults:
Bekform 200/400 Rotacaps
1-2 Rotacaps twice daily

Children above 6 years:
Bekform 200 Rotacaps
1 Rotacap twice daily